swiss medicaXXI century S.A.A man from Romania with severe visual impairment attended Swiss Medica in March 2025. His left eye was his only functional eye and had been affected by glaucoma and optic nerve atrophy.
After his first treatment course, he reported seeing his surroundings more clearly and finding it easier to distinguish shapes and recognize faces.
Clinical Case · Patient overview
Before Treatment: Vision and Main Challenges
The patient had relied on his left eye since childhood, when a penetrating injury led to the surgical removal of his right eye and its replacement with a prosthesis.
Over time, his remaining eye developed several conditions that complicated his vision and care:
- Earlier eye conditions. In 2013, an epimacular membrane—a membrane over the central part of the retina—was diagnosed, alongside inflammatory changes and abnormalities affecting the iris and pupil.
- Changes in vision. In 2022, he developed blurred vision, loss of peripheral vision and difficulty adjusting when moving from bright surroundings into darkness.
- Eye surgery. Following diagnoses of cataract and open-angle glaucoma, he underwent cataract removal with an artificial lens implant, followed by trabeculectomy for glaucoma. Optic nerve atrophy was diagnosed approximately one month after the glaucoma operation.
- Previous treatment. Between 2022 and 2024, he received three courses of conservative treatment intended to prevent further deterioration. According to the patient, he did not notice an improvement in vision after these courses.
By the time he came to Swiss Medica, vision in his only functional eye remained severely impaired and was documented at approximately 25–30%.
Treatment at Swiss Medica
In March 2025, the patient underwent his first regenerative treatment course at Swiss Medica.
Treatment Details
| Component | Administration described in the clinical record |
| Allogeneic placenta-derived MSCs | Intravenous administration |
| Allogeneic umbilical cord-derived MSCs | Intravenous administration |
| MSC-derived exosomes | Intravenous infusion |
| Placenta-derived MSC exosome | Eye drops twice daily |
| Additional therapy | Intracellular metabolism recovery therapy (IMR) |
All procedures were completed without reported complications, and the patient was discharged in stable condition.
He was supplied with exosome-based eye drops to continue local treatment at home for approximately five weeks.
After the First Treatment: What Did the Patient Notice?
Clearer Surroundings
Following his first course, the patient reported that he could see his surroundings more clearly with his left eye.
This was a change from his experience of the previous treatment courses, after which he had not noticed an improvement.
Better Recognition of Shapes and Faces
He also described an improved ability to distinguish shapes and recognize faces.
These were concrete examples of how his vision felt different in daily life. With sight available in only one eye, recognizing more of the people and objects around him was a particularly relevant part of his account.
Overall Outcome
After his first treatment course at Swiss Medica, the patient reported positive changes in the functional vision of his only seeing eye. These practical changes in his everyday visual experience may help him recognize people, orient himself in his surroundings, and perform everyday activities more independently.
Further ophthalmological assessment would be needed to document the extent and persistence of these changes. His glaucoma, optic nerve atrophy, and reliance on one functional eye remained important considerations for ongoing care and monitoring.